Table 3. Correlates of Achieving Viral Suppression (HIV-1 RNA Less Than 400 Copies/mL) Among the Full Buprenorphine Sample.

	All Subjects (N = 266)
	Full Model			Parsimonious Model
	Exp β	CI	ρ	Exp β	CI	ρ
Intercept	0.14	(0.02–0.95)	0.04	0.10	(0.03–0.38)	<0.01
Female gender	1.98	(1.08–3.63)	0.03	1.91	(1.07–3.41)	0.03
Race/ethnicity
Other race	2.16	(0.56–8.41)	NS	2.31	(0.56,9.61)	NS
Asian	3.56	(0.31–40.7)	NS	3.37	(0.23–48.37)	NS
Hispanic	2.71	(1.37–5.37)	<0.01	2.82	(1.44–5.49)	<0.01
White	1.49	(0.77–2.89)	NS	1.49	(0.76–2.91)	NS
Black (referent)	1.00			1.00
Gay/bisexual	0.76	(0.38–1.51)	NS
Used stimulants (cocaine or methamphetamine)	0.83	(0.50–1.38)	NS
Self-reported diagnosis of mental illness	0.91	(0.52–1.59)	NS
Prescribed psychiatric medications	1.34	(0.77–2.34)	NS
Addiction severity—drugs	0.13	(0.02–0.74)	0.02	0.10	(0.02–0.61)	0.01
Being on antiretroviral therapy	9.78	(5.49–17.43)	<0.001	10.27	(5.79–18.23)	<0.001
Bodily pain quality of life (SF-12)	0.99	(0.97–1.01)	NS
General health quality of life (SF-12)	1.03	(1.00–1.05)	0.03	1.02	(1.00–1.04)	0.04
HIV symptom index	0.95	(0.66–1.36)	NS
Buprenorphine prescription during study
One quarter only	1.00
Two quarters only	1.69	(0.63–4.55)	NS
Three quarters only	1.11	(0.57–2.14)	NS
All four quarters	1.32	(0.67–2.59)	NS
Time of observation
Baseline (N = 266)				1.00
Quarter 1				1.07	(0.64–1.79)	NS
Quarter 2				0.86	(0.50–1.48)	NS
Quarter 3				0.98	(0.54–1.80)	NS
Quarter 4				0.89	(0.48–1.65)	NS

P = nonsignificant (NS) is P > 0.05.

CI, confidence interval.